Eplerenone Versus PDT: Comparative Study by OCTA

OCTA in Central Serous Chorioratinopathy Treated With Oral Eplerenone or Hal-fluence Photodynamic Therapy: a Comparative Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05104138

Enrollment

Registered

2021-11-02

Start date

2015-10-01

Completion date

2017-11-30

Last updated

2021-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinopathy

Brief summary

The study aims to analyze the changes in OCTA parameters and in choroidal thickness in patients affected by central serous chorioretinopathy treated by oral eplerenone and half-fluence photodynamic therapy.

Detailed description

Central serous chorioretinopathy (CSC) is a chorioretinal disease characterized by serous detachment due to the dilatation and hyperpermeability of choroidal vessels resulting in the accumulation of serous fluid between the neurosensory retina and the retinal pigment epithelium. Several studies reported the efficacy of half-fluence photodynamic therapy (PDT) and oral eplerenone in the CSC treatment inducing a reduction of the choroidal hyperpermeability and remodeling the choroidal vascularization. This retrospective study aims to perform a quantitative analysis of retinal and CC vessel density by OCTA at baseline, 3 and 6 months in patients underwent PDT and patients underwent eplerenone.

Interventions

DRUGEplerenone

The patients underwent eplerenone treatment for 6 months

DEVICEThe patients underwent half fluence photodynamic therapy for 6 months

Half fluence photodynamic therapy for 6 months

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

30 Years to 60 Years

Inclusion criteria

* age older than 30 years * diagnosis of central serous chorioretinopathy * treatment-naïve with half-fluence photodynamic therapy or oral eplerenone * absence of vitreoretinal and vascular retinal diseases

Exclusion criteria

* age younger than 30 years * absence of diagnosis of central serous chorioretinopathy * previous treatment with half-fluence photodynamic therapy or oral eplerenone * presence of concomitant vitreoretinal and vascular retinal diseases

Design outcomes

Primary

Measure	Time frame	Description
Study of vessel density in retinal choriocapillaris networks, using OCTA, in patients underwent half fluence photodynamic therapy and oral eplerenone	6 months	To evaluate the role of optical coherence tomography angiography in predicting the changes of the vessel density of retinal and choriocapillaris vascular networks , comparing patients underwent half-fluence phodynamic therapy and patients with oral eplerenone. The vessel density are expressed as percentage

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026